Competition & Peer Data API & CSV Delivery

Bellevue Life Sciences Acquisition's Competitiveness

Name: Bellevue Life Sciences Acquisition Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Bellevue Life Sciences Acquisition (BLAC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026

Competitors Tracked

Publicly traded peers

Peer Group Market Share

100.00 %

vs 100.00 % a year ago

Revenue Growth Y/Y

-69.44 %

Q2 2026

Net Margin

-318.07 %

Q2 2026

Key Findings: Bellevue Life Sciences Acquisition vs Its Competitors

TTM: Trailing 12-month revenue of 2M vs -M combined for tracked competitors (100.0% combined share).
Trending: Latest-quarter revenue run-rate is decelerating (-30.2% annualized vs trailing 12 months).
Peer revenue share: Bellevue Life Sciences Acquisition accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

BLAC Sales vs. its Competitors, Q2 2026

Bellevue Life Sciences Acquisition generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/BLAC/competitors                    

                        https://api.csimarket.com/api/v1/companies/BLAC/relationships                    

                        https://api.csimarket.com/api/v1/companies/BLAC/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

For context: the Medical Equipment & Supplies industry grew revenue 15.0% year over year, combined, vs -69.4% for Bellevue Life Sciences Acquisition. Bellevue Life Sciences Acquisition's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.

Bellevue Life Sciences Acquisition's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Bellevue Life Sciences Acquisition Corp	No	No	No	No
Similar Growth & Profitability (8)	0.00 % (0 of 8)	75.00 % (6 of 8)	62.50 % (5 of 8)	37.50 % (3 of 8)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

BLAC Stock Performance relative to its Competitors

BLAC Competitors (weighted) Percent change over the selected range

BLAC Stock Performance relative to Similar Growth & Profitability Competitors

BLAC Similar Growth & Profitability Competitors (equal-weighted, 8) Percent change over the selected range

Bellevue Life Sciences Acquisition's Comment on Competition and Industry Peers

RMC has developed a nationwide sales network and logistics system in South Korea, which supports its distribution of products such as the Chikai Guide Wire from Asahi Intecc, used in neurovascular endovascular therapy. The company operates in a competitive environment that includes pharmaceutical and biotechnology firms as well as public and private research institutions. Competitors may achieve faster regulatory approvals, secure patent protections, or develop drugs with improved efficacy, convenience, cost-effectiveness, or safety. Additionally, competitors may have advantages in manufacturing and marketing their products.

Bellevue Life Sciences Acquisition's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Asahi Intecc	Named by the company	85%	2022 to 2026	3
RMC	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Bellevue Life Sciences Acquisition's named competitors require a Commercial License.

Unlock Commercial Access

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.